Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elbasvir
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C virus (HCV) infection. It is an inhibitor of the HCV non-structural protein 5A (NS5A), a protein essential for viral replication and virion assembly. Elbasvir blocks signaling interactions, redistributes NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modifies the HCV replication complex. It is primarily used in fixed-dose combination with grazoprevir for treating adults and children 12 years or older with chronic HCV genotype 1 or 4 infection[2][3][5][6]. The drug was developed by Merck & Co.
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on elbasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elbasvir.